673 P P
Pill imprint 673 P P has been identified as Cabergoline 0.5 mg.
Cabergoline is used in the treatment of hyperprolactinemia and belongs to the drug classes dopaminergic antiparkinsonism agents, prolactin inhibitors. There is no proven risk in humans during pregnancy.
Cabergoline 0.5 mg is not subject to the Controlled Substances Act.
See also related documents.
Cabergoline Images
- Imprint:
-
673
P P - Strength:
- 0.5 mg
- Color:
- White
- Size:
- 7.00 mm
- Shape:
- Elliptical / Oval
- Availability:
- Prescription only
- Inactive Ingredients:
- citric acid
croscarmellose sodium
magnesium stearate
microcrystalline cellulose
- Drug Class:
- Dopaminergic antiparkinsonism agents
Prolactin inhibitors - Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Par Pharmaceutical Inc.
- National Drug Code (NDC):
- 49884-0673
Advertisement
More Cabergoline resources
- Cabergoline (Wolters Kluwer)
- cabergoline (Cerner Multum)
- cabergoline (Micromedex) - Includes Dosage Information
- Cabergoline (AHFS DI)
- Cabergoline (FDA)
Search Again
